Retatrutide, by Soma Corp., is gaining increasing attention as a potential treatment for metabolic regulation. This dual-action drug merges the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , aiming to not only promote metabolic improvements but also address related metaboli